Site icon Impactiviti

Impactiviti Daily 020110


Tykerb + Femara for breast cancer approved – The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated...more Good for Glaxo on Tykerb, but GSK also announcing thousands more cuts.

UCB to U.S. primary care market: Good-bye now – UCB announced today that it plans to accelerate its U.S. transition to a purely specialty-focused biopharmaceutical company and will exit the primary care market in the U.S., effective 1 March 2010more

Assuming FDA approval, five drugs to watch this year (one already approved).

Boston Scientific to J&JHere’s $1.7B. Are we OK now?


There are so many vendors – who do I choose? – We make it easy for you at Impactiviti. Just give us a call, let us know your training/marketing needs, and we’ll recommend top vendors for you to use. It’s what we do, and it’s free. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.


ePharma Summit, next week in Philadelphia. I’ll be there – how about you?



Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)

Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)

Connect with Steve Woodruff

Exit mobile version